2. Academic Validation
  3. High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv

High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv

  • Tuberculosis (Edinb). 2009 Sep;89(5):334-53. doi: 10.1016/j.tube.2009.05.008.
Subramaniam Ananthan 1,  Ellen R Faaleolea,  Robert C Goldman,  Judith V Hobrath,  Cecil D Kwong,  Barbara E Laughon,  Joseph A Maddry,  Alka Mehta,  Lynn Rasmussen,  Robert C Reynolds,  John A Secrist 3rd,  Nice Shindo,  Dustin N Showe,  Melinda I Sosa,  William J Suling,  E Lucile White
Affiliations

Affiliation

  • 1 Southern Research Institute, 2000 Ninth Avenue South, Birmingham, AL 35205, USA. ananthan@southernresearch.org
PMID: 19758845 DOI: 10.1016/j.tube.2009.05.008
Abstract

There is an urgent need for the discovery and development of new antitubercular agents that target new biochemical pathways and treat drug resistant forms of the disease. One approach to addressing this need is through high-throughput screening of medicinally relevant libraries against the whole bacterium in order to discover a variety of new, active scaffolds that will stimulate new biological research and drug discovery. Through the Tuberculosis Antimicrobial Acquisition and Coordinating Facility (www.taacf.org), a large, medicinally relevant chemical library was screened against M. tuberculosis strain H37Rv. The screening methods and a medicinal chemistry analysis of the results are reported herein.

Figures
Products